ID: h-d4ac0303f6
Hypothesis
G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain
The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact.
EvidencePending (0%)📖 14 cit🗣 1 debates✓ 7 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
The most supported model is that pathogenic G2019S shifts the basal catalytic set-point upward, producing higher baseline phospho-Rab output while leaving the core lysosomal volume-sensing response architecture largely intact. In this view, mutant cells begin from a higher activity floor, and the key experimental discriminator is whether baseline-normalized EC50, slope, or Emax materially increase during graded swelling.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["LRRK2<br/>Primary Target"]
B["Biological Process 1<br/>Mechanistic Step A"]
C["Biological Process 2<br/>Mechanistic Step B"]
D["Output Phenotype<br/>Disease Effect"]
A --> B
B --> C
C --> D
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Endogenous G2019S shows only modest phospho-Rab elevation compared with stronger ROC-COR mutants, consistent with a modest catalytic bias rather than a major gain increase.
Supports
Membrane recruitment is sufficient to trigger Rab phosphorylation, implying recruitment may be the main activation event and G2019S may add a higher baseline set-point onto that pathway.
Supports
Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis.
Supports
ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages.
Supports
Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease.
Supports
The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1.
Contradicts
Existing studies do not cleanly separate baseline offset from stimulus gain under endogenous graded lysosomal swelling conditions.
Contradicts
Elevated phospho-Rab biomarkers in carriers could also reflect altered membrane dwell time, substrate access, or phosphatase balance rather than a simple baseline-only effect.
📖 Linked Papers (8)Export BibTeX ↗
LRRK2 kinase-mediated accumulation of lysosome-associated phospho-Rabs in tauopathies and synucleinopathies.
Acta neuropathologica (2025) · PubMed:41128923 ↗
No figures
RAB12-LRRK2 complex suppresses primary ciliogenesis and regulates centrosome homeostasis in astrocytes.
Nature communications (2024) · PubMed:39343966 ↗
No figures
Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease.
Mov Disord (2022) · PubMed:35521944 ↗
No figures
Exploring the focal role of LRRK2 kinase in Parkinson's disease.
Environmental science and pollution research international (2022) · PubMed:35147886 ↗
No figures
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
International journal of molecular sciences (2020) · PubMed:33182554 ↗
No figures
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.
International journal of molecular sciences (2020) · PubMed:33182554 ↗
No figures
Rab GTPases as Physiological Substrates of LRRK2 Kinase.
Exp Neurobiol (2019) · PubMed:31138985 ↗
No figures
Multiple Sclerosis Pathology.
Cold Spring Harbor perspectives in medicine (2018) · PubMed:29358320 ↗
No figures
🏥 Translation
🧬 3D Protein Structure — LRRK2
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for LRRK2 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRRK2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.8%
Volatility
Low
0.0080
Events (7d)
3
Price History
▼22.1%💾 Resource Usage
LLM Tokens
18,998
$0.0570
Total Cost
$0.0570
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF G2019S and WT cells are treated with graded concentrations of osmotic lysosomal stressors (mannitol, sucrose, or nigericin) for 2-24 hours, THEN the baseline-normalized dose-response curve for phos | Normalized EC50, Emax, and Hill slope for phospho-Rab10 induction will be comparable between G2019S and WT (difference < 20%) | — no observation — | pending | 0.65 |
| IF primary fibroblasts or iPSC-derived neurons carrying G2019S LRRK2 are compared to isogenic wild-type controls, THEN phospho-Rab10 (Ser106) or phospho-Rab8A (Ser72) levels will be significantly elev | Baseline phospho-Rab10/Rab8A levels will be higher in G2019S carriers than in isogenic controls | — no observation — | pending | 0.75 |
🔮 Falsifiable Predictions (2)
pendingconf 75%
IF primary fibroblasts or iPSC-derived neurons carrying G2019S LRRK2 are compared to isogenic wild-type controls, THEN phospho-Rab10 (Ser106) or phospho-Rab8A (Ser72) levels will be significantly elevated at baseline (no lysosomal stress) by at least 30-50% as measured by quantitative immunoblot or
Predicted outcome: Baseline phospho-Rab10/Rab8A levels will be higher in G2019S carriers than in isogenic controls
Falsification: No significant difference in baseline phospho-Rab10/Rab8A levels between G2019S and WT cells (t-test p > 0.05 or fold-change < 1.3)
pendingconf 65%
IF G2019S and WT cells are treated with graded concentrations of osmotic lysosomal stressors (mannitol, sucrose, or nigericin) for 2-24 hours, THEN the baseline-normalized dose-response curve for phospho-Rab10 will show no material increase in EC50, Emax, or Hill slope in G2019S versus WT, WITHIN 6
Predicted outcome: Normalized EC50, Emax, and Hill slope for phospho-Rab10 induction will be comparable between G2019S and WT (difference < 20%)
Falsification: G2019S cells show >20% increase in baseline-normalized Emax or >2-fold leftward shift in EC50, or significantly steeper Hill slope, indicating true amplification of the swelling response rather than m
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.